GIYEN-BARRE SINDROMINING KLINIK XUSUSIYATLARI, KECHISHI VA DIAGNOSTIKASI
##article.subject##:
Miller-Fisher sindromi, o'tkir motor aksonal neyropati (O’MAN), intravenoz immunoglobulin, gangliozid antitela##article.abstract##
Giyen-Barre sindromi (GGb) - periferik asab tizimining demiyelinatsiyasi va asosan sog'lom odamlarda paydo bo'ladigan progressiv mushaklarning zaifligi bilan bog'liq bo'lgan juda kam uchraydigan autoimmun kasallik. GBS yiliga 100 000 odam boshiga 1,1-1,8 holat uchraydi, yosh bilan kasallik soni ham ortadi. GBS klinik spektri geterogen bo'lib, o'tkir yallig'lanishli demyelinatsion polinevropatiya (O’YDP), o'tkir motor aksonal neyropatiya (O’MAN), o'tkir motor va sensor aksonal neyropatiya (O’MSAN) va Miller Fisher sindromi (MFS) ni o'z ichiga oladi. Kasallik odatda bir necha kundan 4 haftagacha davom etadigan va har qanday yoshdagi bemorlarda uchraydigan nosimmetrik ekstremal zaiflikning tez boshlanishi bilan tavsiflanadi. Rivojlangan mamlakatlarda GBS o'tkir zaif falajning eng keng tarqalgan turi bo'ldi. Kasallikni tez aniqlash va davolanishiga qaramasdan, GBS jiddiy kasallik bo'lib qolmoqda.
Библиографические ссылки
Hughes R.A., Cornblath D.R., Guillain-barre syndrome. The Lancet, 2005; 366(9497): 1653-66.
Govoni V., Granieri E., Epidemiology of the Guillain-Barré syndrome. Current opinion in
neurology, 2001; 14(5): 605-13.
Guillain-Barré Syndrome: Indications for Plasma Exchange. Transfusion Science, 1999; 20: 53–61.
Hughes R.A., Swan A.V., van Doorn P.A., Intravenous immunoglobulin for Guillain‐Barré
syndrome. The Cochrane Library, 2010.
Tsang, R.S. The relationship of Campylobacter jejuni infection and the development of GuillianBarré syndrome. Curr. Opin. Infect. Dis, 2002; 15: 221-228.
Meythaler J.M., Rehabilitation of Guillain-Barré syndrome. Archives of physical medicine and rehabilitation, 1997; 78(8): 872-9.
Raphaël J.C., Chevret S., Hughes R., Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev., 2002; 2(2).
Rees J.H., Soudain S.E., Gregson N.A., Hughes R.A. Campylobacter jejuni infection and Guillain–Barré syndrome. New England Journal of Medicine, 1995; 333(21): 1374-9.
Reilly M., Hutchinson M., Suxamethonium is contraindicated in the Guillain-Barré syndrome. Journal of neurology, neurosurgery, and psychiatry, 1991; 54(11): 1018.
Haymaker WE, Kernohan JW. The Landry-GuillainBarré syndrome; a clinicopathologic report of 50 fatal cases and a critique of the literature. Medicine (Baltimore), 1949; 28(1): 59-141.
Sinhaa S, Prasada KN, Pradhanb S, Jaina D, Jhab S.Detection of preceding Campylobacter jejuni infection by polymerase chain reaction in patients with Guillain-Barré syndrome. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2004; 98: 342—346.
McGrogan A., Madle G., SeОМАН H., DeVries C.S. Epidemiology of Guillain-Barré Syndrome worldwide. A systemic literature review. Neuroepidemiology, 2009; 32: 150-63.
Toft CE. Guillian-Barré Syndrome – a case study. Accident and Emergency Nursing, 2002; 10(2): 92- 102.
Parkin RT, Davies-Cole JO, Balbus JM. A definition for chronic sequelae applied to campylobacter and guillian-barre syndrome (СГБ). Annals of Epidemiology, 2000; 10(7): 473.
Brody AJ, Sternbach G, Varon J. Octave landry: Guillain-Barré syndrome. The Journal of Emergency Medicine, 1994; 12(6).
Hahn AF, FRCPC. Guillian-Barre’ syndrome. The Lancet, 1998; 325(9128): 635-641.17. Taylor WA, Brostoff SW, Hughes RAC. P2 specific lymphocyte transformation in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. Journal of the Neurological Sciences, 1991; 104(1): 52-5.
Shahar E, Shorer Z, Roifman CM, Levi Y, Brand N, Ravid S, et al. Immune globulins are effective in severe pediatric Guillain-Barre syndrome. Pediatriс Neurology, 1997; 16(1): 32-6.
Pascuzzi RM, Fleck JD. Acute peripheral neuropathy in adults: Guillain-Barré Syndrome and Related Disorders. Neurologic Clinics, 1997; 15(3): 529-47.
Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain–Barré syndrome. New England Journal of Medicine, 1995; 333(21): 1374-9.
Looney RJ, Huggins J. Use of intravenous immunoglobulin G (IVIG). Best Practice & Research Clinical Haematology, 2006; 19(1): 3-25.
Katri B, Koontz D. Disorders of the peripheral nerves. In: Daroff RB, Fenichel GM, Jankovic J,Mazziotta JC, eds. Bradley's Neurology in Clinical Practice. 6th ed. Philadelphia, PA: Elsevier Saunders, 2012; 76.
Hughes R, FMedSci, Cornblath DR. Guillain-Barré syndrome. The Lancet, 2005; 366(9497): 1653–1666.
Kuwabara S. Guillain-Barré Syndrome Epidemiology, Pathophysiology and Management. Drugs, 2004; 64(6): 597-610.
Hughes R, van der Meche FG. Corticosteroids for treating Guillain-Barré syndrome. Cochrane Database Syst Rev., 2000; 2: 001446. 26. Прокоп, Галански. Спиральная и многослойная компьютерная томография (в двух томах), Москва. = 2009. = I том – 413 с. II том. – 710с.
